Rain Therapeutics, Inc. (RAIN)
|Net Income (ttm)||-21.08M|
The news comes months after the company closed a $63 million Series B and inlicensed RAIN-32 from Daiichi Sankyo.
Rain Therapeutics headlines newest slate of IPO-bound biotechs with $100M penciled in for lead oncology program
A fresh slate of biotech IPOs has filed to go public as the calendar turns toward the second quarter.
Rain Therapeutics, Inc. has filed to go public with an IPO on the NASDAQ.
Rain Therapeutics is a clinical-stage precision oncology company developing therapies that target oncogenic drivers for which we are able to genetically select patients we believe will most likely benefit. This approach includes using a tumor-agnostic strategy to select patients based on their tumors’ underlying genetics rather than histology. We have in-licensed product candidates, each with a differentiated profile relative to available therapies, and we intend to continue strengthening our pipeline through focused business development and ... [Read more...]
|IPO Date |
Apr 23, 2021
|Stock Exchange |
|Ticker Symbol |